Comment from Bhasker Sambar

Summary: Bhasker Sambar, a pharmaceutical development and CMC operations manager, provides specific recommendations to improve the draft guidance on AI in regulatory decision-making. He suggests expanding the scope to include combination products, extending practical examples through all steps, clarifying requirements for third-party AI models, and addressing cybersecurity risks.